SGS, a leading bio/pharmaceutical analytical and bioanalytical contract solutions provider, announced that it is to invest in a new facility in Berlin, Germany, to expand its R&D/QC testing activities and to offer new analytical services to clients.
The laboratories are due to open mid-2017, and will replace the current 2,500 sq. m. facility in the city which was opened in 1985, and offers a variety of analytical services to the pharmaceutical and related industries.
The laboratory will operate under cGMP and has the potential to expand the workforce and capacity by one-third. Its construction has been triggered by increased demand in stability testing, the handling of cytotoxic substances for oncology drug products, elemental impurity testing according to USP<232>, USP <233>, ICH Q3D (Step 4), particle testing and container testing according to USP and Ph.Eur.
“The Berlin facility has always had a core expertise in stability testing of drug products, but the forecasted demand in this area means investment is crucial for SGS to maintain current and future client relationships,” commented Dr. Sheida Hoenlinger, Director, Life Sciences Germany. “The new facility also gives the opportunity to expand in important growth areas like oncology drug products and stability studies.”
This investment follows the recent announcement by SGS that it has opened a new facility in Wiesbaden, Germany, as a dedicated Global Center of Excellence for the testing of extractables and leachables within pharmaceutical products.
With 21 laboratories offering contract analytical and bioanalytical services, SGS leverages its wholly-owned global network, present in North America, Europe, and Asia, to deliver harmonized solutions to large pharmaceutical and biotechnology firms. In addition to testing services for the bio/pharmaceutical market, SGS also provides Phase I-IV clinical trial management, and services encompassing data management and statistics, PK/PD modeling and simulation, pharmacovigilance and regulatory consultancy.
To view the full press release, click here.